Biohaven's taldefgrobep alfa receives eu orphan drug designation for spinal muscular atrophy

Taldefgrobep alfa, in phase 3 global clinical development for spinal muscular atrophy, granted eu orphan drug designation in addition to previously receiving fast track and orphan drug designation in the us new haven, conn. , july 31, 2023 /prnewswire/ -- biohaven ltd.
BHVN Ratings Summary
BHVN Quant Ranking